uploads///Chart

Gilead Sciences’ HIV and HBV Products in 4Q17

By

Mar. 6 2018, Updated 3:25 p.m. ET

Gilead Sciences’ portfolio  

Gilead Sciences’ (GILD) antiviral drug portfolio includes HIV products, HBV (Hepatitis B virus) products, and HCV (Hepatitis C virus) products.

The above chart compares the revenues for key products from the HIV and HBV portfolio since 1Q17.

Article continues below advertisement

HIV and HBV products

Gilead Sciences’ HIV and HBV infection products portfolio includes various products like Descovy, Genvoya, Odefsey, Atripla, Truvada, Viread, Stribild, and Complera.

Genvoya

Genvoya is approved as a first-line treatment for HIV-1 infections and existing HIV-1 infections. Genvoya reported revenues of $1.06 billion during 4Q17—88.3% growth compared to revenues of $563 million during 4Q16. US markets reported Genvoya sales of $844 million, while European markets reported $176 million from Genvoya sales during 4Q17.

Article continues below advertisement

Atripla

Atripla is approved to treat patients with HIV-1 infections. Atripla is used as a monotherapy and in combination with other antiretroviral drugs. Atripla reported sales of $440 million during 4Q17—a 27.5% decline compared to $607 million during 4Q16. The decline in Atripla’s sales was due to lower sales across all of the markets worldwide.

Truvada

Truvada is used in combination with other antiretroviral drugs to treat HIV-1 infections and reduce the risk of sexually acquired HIV-1 infections. Truvada reported sales of $797 million during 4Q17—an 8.2% decline compared to $868 million during 4Q16. The decline was driven by lower Truvada sales in European and international markets. The decline was partially offset by Truvada’s strong sales in US markets during 4Q17.

Article continues below advertisement

Stribild

Stribild is a drug that treats HIV-1 infections. Stribild reported revenues of $222 million during 4Q17—a 42.6% decline compared to $387 million during 4Q16. The decline was driven by Stribild’s lower sales across all of the major markets worldwide.

Viread

Viread is approved to treat HBV infections. Viread reported revenues of $212 million during 4Q17—a 34.6% decline in revenues compared to $324 million during 4Q16. The decline in Viread’s sales was driven by lower sales across all of the major markets worldwide.

A few other HBV drugs include Bristol-Myers Squibb’s (BMY) Baraclude, Merck’s (MRK) PegIntron, and GlaxoSmithKline’s (GSK) Epivir HBV.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.